Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase

Abstract Influenza epidemics are responsible for an average of 3–5 millions of severe cases and up to 500,000 deaths around the world. One of flu pandemic types is influenza A(H1N1)pdm09 virus (pdm09H1N1). Oseltamivir is the antiviral drug used to treat influenza targeting at neuraminidase (NA) located on the viral surface. Influenza virus undergoes high mutation rates and leads to drug resistance, and thus the development of more efficient drugs is required. In the present study, all-atom molecular dynamics simulations were applied to understand the oseltamivir resistance caused by the single E119D and double E119D/H274Y mutations on NA. The obtained results in terms of binding free energy and intermolecular interactions in the ligand–protein interface showed that the oseltamivir could not be well accommodated in the binding pocket of both NA mutants and the 150-loop moves out from oseltamivir as an “open” state. A greater number of water molecules accessible to the binding pocket could disrupt the oseltamivir binding with NA target as seen be high mobility of oseltamivir at the active site. Additionally, our finding could guide to the design and development of novel NA inhibitor drugs. Graphic abstract

[1]  L. Nilsson,et al.  Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K , 2001 .

[2]  Saikiran Reddy Peddi,et al.  Molecular dynamics and MM/GBSA-integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors , 2018, Journal of biomolecular structure & dynamics.

[3]  R. Webster,et al.  Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses , 2006, Journal of Virology.

[4]  Vasanthanathan Poongavanam,et al.  Viral M2 ion channel protein: a promising target for anti-influenza drug discovery. , 2014, Mini reviews in medicinal chemistry.

[5]  C. Beauchemin,et al.  The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients , 2017, Scientific Reports.

[6]  D. Dou,et al.  Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement , 2018, Front. Immunol..

[7]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[8]  Fumio Hirata,et al.  Placevent: An algorithm for prediction of explicit solvent atom distribution—Application to HIV‐1 protease and F‐ATP synthase , 2012, J. Comput. Chem..

[9]  George F. Gao,et al.  Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition , 2011, PLoS pathogens.

[10]  Julian Tirado-Rives,et al.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. , 2002, Journal of medicinal chemistry.

[11]  J. Mosse,et al.  Selection of Multi-Drug Resistant Influenza A and B Viruses under Zanamivir Pressure and their Replication Fitness in Ferrets , 2018, Antiviral therapy.

[12]  P Mark,et al.  298KでのTIP3P,SPC及びSPC/E水モデルの構造及び動力学 , 2001 .

[13]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[14]  R. Mandal,et al.  In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein , 2018, Journal of biomolecular structure & dynamics.

[15]  Thanyada Rungrotmongkol,et al.  Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach , 2010, Amino Acids.

[16]  E. Coutinho,et al.  Search for novel neuraminidase inhibitors: Design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods. , 2009, Biochimica et biophysica acta.

[17]  Jianhua He,et al.  Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses , 2013, Cell Research.

[18]  Gustavo Hernandez-Mejia,et al.  Neuraminidase Inhibitors in Influenza Treatment and Prevention–Is It Time to Call It a Day? , 2018, Viruses.

[19]  R. Webby,et al.  Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes , 2017, Journal of Virology.

[20]  A. Eliseev,et al.  Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[22]  Thanyada Rungrotmongkol,et al.  How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? , 2009, Biophysical chemistry.

[23]  V. Shanthi,et al.  Exploring the Cause of Oseltamivir Resistance Against Mutant H274Y Neuraminidase by Molecular Simulation Approach , 2012, Applied Biochemistry and Biotechnology.

[24]  Asimul Islam,et al.  A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states. , 2014, Current protein & peptide science.

[25]  Xiaowu Chen,et al.  Neuraminidase Inhibitors as Anti-Influenza Virus Agents , 1999, Antiviral chemistry & chemotherapy.

[26]  Thanyada Rungrotmongkol,et al.  Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues , 2009, J. Chem. Inf. Model..

[27]  Carlos Simmerling,et al.  Grid-based backbone correction to the ff12SB protein force field for implicit-solvent simulations. , 2015, Journal of chemical theory and computation.

[28]  George F. Gao,et al.  Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding , 2013, Scientific Reports.

[29]  T. Rungrotmongkol,et al.  Computational screening of fatty acid synthase inhibitors against thioesterase domain , 2017, Journal of biomolecular structure & dynamics.

[30]  S. Carver,et al.  Feline Leukemia Virus (FeLV) Disease Outcomes in a Domestic Cat Breeding Colony: Relationship to Endogenous FeLV and Other Chronic Viral Infections , 2018, Journal of Virology.

[31]  Tom J. Petty,et al.  E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. , 2015, The Journal of infectious diseases.

[32]  G. Kobinger,et al.  Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets , 2010, PLoS pathogens.

[33]  Thanyada Rungrotmongkol,et al.  Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study , 2016, Journal of Computer-Aided Molecular Design.

[34]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[35]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[36]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[37]  Kazuki Saito,et al.  Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations. , 2015, Phytochemistry.

[38]  Kuo-Chen Chou,et al.  Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. , 2007, Biochemical and biophysical research communications.

[39]  M. Xia,et al.  Tulane virus recognizes sialic acids as cellular receptors , 2015, Scientific Reports.

[40]  Weiqi Wang,et al.  New small-molecule drug design strategies for fighting resistant influenza A , 2015, Acta pharmaceutica Sinica. B.

[41]  T. Rungrotmongkol,et al.  Structure–Activity Relationships and Molecular Docking Analysis of Mcl-1 Targeting Renieramycin T Analogues in Patient-derived Lung Cancer Cells , 2020, Cancers.

[42]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[43]  G. Boivin,et al.  Influenza virus resistance to neuraminidase inhibitors. , 2013, Antiviral research.

[44]  G. Gao,et al.  Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor , 2016, Journal of Virology.

[45]  P. Collins,et al.  H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis , 2012, PLoS pathogens.

[46]  Gerhard Hummer,et al.  Native contacts determine protein folding mechanisms in atomistic simulations , 2013, Proceedings of the National Academy of Sciences.

[47]  Daniel J. Sindhikara,et al.  A 3D‐RISM/RISM study of the oseltamivir binding efficiency with the wild‐type and resistance‐associated mutant forms of the viral influenza B neuraminidase , 2016, Protein science : a publication of the Protein Society.

[48]  Kuk Jin Park,et al.  Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors , 2014, Journal of Virology.